The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | The development of clinical guidelines for older patients with AML
In this video, Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York, NY, shares her insights on a discussion held at ASH 2021, which focused on the development of guidelines for older patients with acute myeloid leukemia (AML). First, Dr Desai gives a detailed description of the process behind developing these guidelines, which were formed using a rigorous meta-analysis, and involved answering a variety of specific questions. Following this, Dr Desai goes on to explain what was presented at ASH, and briefly mentions the need to regularly update the guidelines based on novel data, such as FLT3 inhibitors and oral azacitidine. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
